KORU Medical Systems (NASDAQ:KRMD – Get Free Report) issued its earnings results on Wednesday. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03, Zacks reports. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $11.62 million.
Here are the key takeaways from KORU Medical Systems’ conference call:
- Q2 revenue reached a record $12 million, up 18% year over year, driven by 12% growth in domestic core revenue and 59% international growth. Management said domestic demand, patient retention, new starts, and market-share gains remain strong.
- Gross margin improved to 65.1% from 63.5% a year ago, supported by manufacturing efficiencies, pricing, mix, and improved supplier terms. KORU also reported positive net income for the first time since 2019, positive operating cash flow in the quarter, and reiterated expectations for positive adjusted EBITDA for the full year.
- The company narrowed 2026 revenue guidance to $47.5 million-$48.5 million from its prior outlook, citing slower-than-expected launches in certain international, non-tender markets. Management now expects some of that prefilled-syringe opportunity to contribute more meaningfully in 2027.
- KORU withdrew its U.S. PHESGO 510(k) application after discussions with the FDA and will pursue other oncology biologics instead, delaying its planned U.S. oncology entry. PHESGO remains part of the international strategy, but additional real-world evidence and regulatory work are required.
- The company acquired connected-monitoring technology intended to add adherence tracking, real-world evidence, and patient support to its infusion platform, though management characterized it as a multi-year development effort. KORU also said Freedom 360 development has cleared its highest-risk stages and remains on track for a U.S. 510(k) submission by the end of 2027.
KORU Medical Systems Stock Performance
KORU Medical Systems stock traded down $0.57 during trading on Thursday, reaching $3.56. 1,075,072 shares of the company’s stock were exchanged, compared to its average volume of 166,755. The company’s 50-day moving average is $4.12 and its two-hundred day moving average is $4.37. KORU Medical Systems has a 52-week low of $3.21 and a 52-week high of $6.61. The firm has a market cap of $163.52 million, a price-to-earnings ratio of -71.20 and a beta of 0.45.
Insider Buying and Selling
Institutional Investors Weigh In On KORU Medical Systems
Large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC lifted its position in KORU Medical Systems by 927.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock worth $196,000 after acquiring an additional 69,758 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in KORU Medical Systems by 189.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after buying an additional 158,914 shares in the last quarter. Jane Street Group LLC lifted its holdings in KORU Medical Systems by 136.7% in the 1st quarter. Jane Street Group LLC now owns 163,137 shares of the company’s stock worth $414,000 after buying an additional 94,214 shares in the last quarter. Acadian Asset Management LLC purchased a new position in KORU Medical Systems in the 1st quarter valued at about $63,000. Finally, Geode Capital Management LLC boosted its holdings in KORU Medical Systems by 101.3% in the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after purchasing an additional 501,875 shares during the last quarter. Institutional investors and hedge funds own 58.60% of the company’s stock.
Analyst Upgrades and Downgrades
KRMD has been the subject of several research analyst reports. Wall Street Zen upgraded KORU Medical Systems from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Craig Hallum reiterated a “buy” rating and set a $6.00 target price on shares of KORU Medical Systems in a report on Thursday. Finally, Weiss Ratings raised shares of KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.00.
Check Out Our Latest Research Report on KRMD
About KORU Medical Systems
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.
Featured Stories
- Five stocks we like better than KORU Medical Systems
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
